Palatin Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.7M
- Price
- $9.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +6.30%
- Volume
- 11.9K
About
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Quick stats
Shares outstanding1.8M
Computed float1.6M
Float / shares92.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000911216
Websitehttps://palatin.com
AI Summary
AI-generated1/4
minorbullishother
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Recent M&A activity, including Neurocrine's $2.9 billion acquisition of Soleno and Vertex's $10 billion acquisition of Crinetics, has validated the rare endocrine market and highlighted the value of MC4R agonists.
Palatin is advancing two next-generation MC4R-selective candidates, targeting IND submissions in Q4 2026 and the first half of 2027, with the goal of improving tolerability over existing therapies.
The company aims to differentiate its pipeline by minimizing hyperpigmentation and gastrointestinal side effects common in current treatments, positioning itself for potential best-in-class status in rare obesity disorders.
Red flags
- Paid promotional content (Wall Street Wire receives cash compensation from Palatin Technologies)
- Programs are preclinical; clinical success and regulatory approval remain uncertain
- Article is not an official company communication